Quest Diagnostics (DGX) Q3 FY2023 earnings: revenue $2.3 billion, down 7.7% on the year
Quest Diagnostics Inc. (DGX) reported revenue of $2.3 billion for Q3 FY2023, the quarter ended 30 September 2023, down 7.7% on the same quarter a year earlier. Net income was $225 million, down 12.1% on the year, and diluted earnings per share $1.96. The figures are the company's own, from the 10-Q it filed with the SEC on 25 October 2023.
Revenue
$2.3 billion
-7.7% on the year · -1.8% on the quarter
Q4 FY2021Q3 FY2023
Operating margin
14.9%
15.8% a year earlier
Q4 FY2021Q3 FY2023
Net income
$225 million
-12.1% on the year · -4.3% on the quarter
Q4 FY2021Q3 FY2023
Diluted EPS
$1.96
-9.7% on the year · -4.4% on the quarter
Q4 FY2021Q3 FY2023
this quarterthe same quarter a year earlierHover a bar for its figure.
Income statement (profit and loss)
$ million
Q3 FY2023
Q2 FY2023
Q3 FY2022
On the quarter
On the year
Last 8 quarters
Revenue
2,295
2,338
2,486
-1.8%
-7.7%
Cost of revenue
1,541
1,546
1,618
-0.3%
-4.8%
Gross profit
754
792
868
-4.8%
-13.1%
Gross margin
32.9%
33.9%
34.9%
Selling, general and administrative
380
416
464
-8.7%
-18.1%
Operating income
342
348
392
-1.7%
-12.8%
Operating margin
14.9%
14.9%
15.8%
Interest expense
41.0
39.0
37.0
+5.1%
+10.8%
Pre-tax income
299
317
351
-5.7%
-14.8%
Income tax
68.0
75.0
81.0
-9.3%
-16.0%
Effective tax rate
22.7%
23.7%
23.1%
Net income
225
235
256
-4.3%
-12.1%
Net margin
9.8%
10.1%
10.3%
Diluted EPS
$1.96
$2.05
$2.17
-4.4%
-9.7%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
Q3 FY2023
Q2 FY2023
Q3 FY2022
On the quarter
On the year
Last 8 quarters
Operating cash flow
207
444
502
-53.4%
-58.8%
Capital expenditure
105
104
118
+1.0%
-11.0%
Free cash flow
102
340
384
-70.0%
-73.4%
Free cash flow margin
4.4%
14.5%
15.4%
Cash from investing
-107
-682
-118
Cash from financing
-83.0
189
-474
Depreciation and amortisation
111
112
108
-0.9%
+2.8%
Share-based compensation
18.0
16.0
18.0
+12.5%
0.0%
Buybacks
0.0
0.0
374
Dividends paid
80.0
80.0
78.0
0.0%
+2.6%
Dividend per share
$0.71
$0.71
$0.66
0.0%
+7.6%
Diluted shares, weighted
114m
114m
118m
0.0%
-3.4%
Shares outstanding at period end
112m
112m
114m
+0.2%
-1.3%
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
$ million
Q3 FY2023
Q2 FY2023
Q3 FY2022
On the quarter
On the year
Last 8 quarters
Shareholders' equity
6,425
6,249
6,235
+2.8%
+3.0%
Non-controlling interest
38.0
38.0
37.0
0.0%
+2.7%
Redeemable equity
76.0
77.0
77.0
-1.3%
-1.3%
Debt
4,250
4,295
3,980
-1.0%
+6.8%
Operating lease liabilities
505
508
505
-0.6%
0.0%
Other liabilities
2,188
2,258
2,389
-3.1%
-8.4%
Total liabilities and equity
13,482
13,425
13,223
+0.4%
+2.0%
Fixed assets
1,830
1,814
1,707
+0.9%
+7.2%
Goodwill
7,732
7,733
7,190
-0.0%
+7.5%
Intangible assets
1,219
1,247
1,115
-2.2%
+9.3%
Cash and equivalents
143
126
700
+13.5%
-79.6%
Receivables
1,281
1,235
1,280
+3.7%
+0.1%
Inventory
184
184
183
0.0%
+0.5%
Other assets
1,093
1,086
1,048
+0.6%
+4.3%
Total assets
13,482
13,425
13,223
+0.4%
+2.0%
Questions
What was Quest Diagnostics' revenue in Q3 FY2023?
Quest Diagnostics (DGX) reported revenue of $2.3 billion for Q3 FY2023, the quarter ended 30 September 2023, down 7.7% on the same quarter a year earlier.
How much did Quest Diagnostics earn in Q3 FY2023?
Net income for Q3 FY2023 was $225 million, down 12.1% on the year, and diluted earnings per share $1.96.
When did Quest Diagnostics report Q3 FY2023 results?
Quest Diagnostics filed its 10-Q for the quarter ended 30 September 2023 with the SEC on 25 October 2023.
Each quarter as filed, linked to its filing. Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.
10-Q for the period ended 30 September 2023, filed 25 October 2023: the filing.